Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)

Next Previous
Trial Profile

Belatacept for the Management of Moderately Sensitized Patients at Risk for Delayed Graft Function (DGF)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 May 2016

At a glance

  • Drugs Belatacept (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms BelatPilot

    • Most Recent Events

    • 08 Jul 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top